5,6,7,8-tetrahydro-9-t-butyl-2,4-di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indole | 157014-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5,6,7,8-tetrahydro-9-t-butyl-2,4-di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indole
• 英文别名: 9-tert-Butyl-2,4-di(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indole；9-tert-butyl-2,4-dipyrrolidin-1-yl-5,6,7,8-tetrahydropyrimido[4,5-b]indole
• CAS: 157014-50-1
• 化学式: C₂₂H₃₃N₅
• 分子量: 367.538
• InChiKey: AABHDKKHKFNNGK-UHFFFAOYSA-N

物化性质

• 沸点：
  572.2±60.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  37.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5,6,7,8-tetrahydro-9-t-butyl-2,4-di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indole 在 正丁基锂 、 palladium 10% on activated carbon 、 三氟乙酸 、 萘烷 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 8.75h， 生成 2-(2,4-Di-1-pyrrolidinyl-9H-pyrimido(4,5-b)indol-9-yl)-1-(1-pyrrolidinyl)ethanone
  参考文献：
  名称：

  Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A

  摘要：

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.

  DOI：

  10.1021/op000221p
• 作为产物：
  描述：

  2,4-di(1-pyrrolidinyl)-6-chloropyrimidine 在 正丁基锂 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 正己烷 、 乙腈 为溶剂， 反应 42.25h， 生成 5,6,7,8-tetrahydro-9-t-butyl-2,4-di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indole
  参考文献：
  名称：

  Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A

  摘要：

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.

  DOI：

  10.1021/op000221p

文献信息

• Pyrimido\x9b4,5-B!indoles
  申请人：Pharmacia & Upjohn Company

  公开号：US05795986A1

  公开（公告）日：1998-08-18

  The pyrimido\x9b4,5-b!indoles (I) ##STR1## and lactams (XIII) of the invention are useful as pharmaceutical agents for a number of different indications.

  这个句子的中文翻译如下： 该发明中的嘧啶并[4,5-b]吲哚(I) ## STR1 ## 和内酰胺(XIII)可用作多种不同指示的医药制剂。
• Synthesis of 2,4-Di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indoles, Including Antiasthma Clinical Candidate PNU-142731A
  作者：Gordon L. Bundy、Lee S. Banitt、Paul J. Dobrowolski、John R. Palmer、Theresa M. Schwartz、David C. Zimmermann、Michael F. Lipton、Michael A. Mauragis、Michael F. Veley、Robert B. Appell、Robert C. Clouse、Edward D. Daugs

  DOI：10.1021/op000221p

  日期：2001.3.1

  Two syntheses are described for 1-[(2,4.di-1-pyrrolidinyl-9H-pyrimido[4,5-b]indol-9-yl)-acetyl]pyrrolidine hydrochloride (PNU-142731A), a clinical candidate in the asthma area. The route involving the initial regioselective addition of glycine ethyl ester to commercially available 2,4,6-trichloropyrimidine is particularly well suited for large-scale operation, as it is short, proceeds in good yield, is operationally straightforward, and requires no chromatographic purification of intermediates.